

Name of Journal: *World Journal of Gastroenterology*

Number NO: 39087

Manuscript type: REVIEW

Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases

Jason Reinglas, Lorant Gonczi, Zsuzsanna Kurt, Talat Bessissow, Peter L Lakatos

Abstract

The past decade has brought substantial advances in the management of inflammatory bowel diseases (IBD). The introduction of tumor necrosis factor (TNF) antagonists, evidence for the value of combination therapy, the recognition of targeting lymphocyte trafficking and activation as a viable treatment, and the need for early treatment of high-risk patients are all fundamental concepts for current modern IBD treatment algorithms. In this article, authors review the existing data on approved biologicals and small molecules as well as provide insight on the current positioning of approved

Match Overview

1	Crossref 124 words Pieter Hindryckx, Niels Vande Castele, Gregor Novak, Reena Khanna et al. "The expanding therapeutic armamentarium"	2%
2	Crossref 93 words Marjolijn Duijvestein, Robert Battat, Niels Vande Castele, Geert R. D'Haens et al. "Novel Therapies and Treatment ..."	1%
3	Crossref 25 words Pieter Hindryckx, Niels Vande Castele, Gregor Novak, Reena Khanna et al. "The Expanding Therapeutic Armamentarium"	<1%

找到约 173,000 条结果 (用时 0.41 秒)

Biologic targeting in the treatment of inflammatory bowel diseases

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726060/> - 翻译此页

作者: M Bosani - 2009 - 被引用次数: 146 - 相关文章

2009年7月13日 - The etiology of **inflammatory bowel disease** (IBD) has not yet been ... exploring the safety and efficacy of **old and new biologic** agents, and and fusions proteins.79 These **small molecules** can be screened for a the disease course, but more data are needed before it is **positioned** as a first-line therapy.

Biologic targeting in the treatment of inflammatory bowel diseases.

<https://www.ncbi.nlm.nih.gov/pubmed/19707398> - 翻译此页

作者: M Bosani - 2009 - 被引用次数: 146 - 相关文章

2009年7月13日 - **Biologic** targeting in the **treatment of inflammatory bowel diseases**. ... The etiology of **inflammatory bowel disease** (IBD) has not yet been clarified and ... adhesion **molecules** is a novel and promising strategy to treat Crohn's disease. ... exploring the safety and efficacy of **old and new biologic** agents, and the ...

缺少字词: positioning small

Established Management Paradigms in IBD: Treatment ... - Nature

<https://www.nature.com/articles/ajgsup201616.pdf?origin=ppub> - 翻译此页

作者: MD Regueiro - 2016 - 被引用次数: 2 - 相关文章

INTRODUCTION. **Inflammatory bowel disease** affects approximately 1.6 million ... of 263 per 100,000 individuals in those **aged** over 20 years **old** and of Crohn's ...

Established Management Paradigms in IBD: Treatment Targets and ...

<https://www.nature.com> > ... > clinical and systematic review - 翻译此页

作者: MD Regueiro - 2016 - 被引用次数: 2 - 相关文章

2016年12月1日 - **Inflammatory bowel disease** affects 1.6 million Americans. ... individuals in those **aged** over 20 years **old** and of Crohn's disease in ... The patient enters clinical remission on a combination of **biologic** and immunosuppressive **treatment** but, ... the differences were **small** and of uncertain clinical relevance.

[PDF] Inflammatory Bowel Disease 2016 What's In The Pipeline?

online.ccfa.org/site/.../CCFA_Ingle_5_2016_--_What_s_New_IBD.pdf - 翻译此页

2016年5月9日 - It takes years for **new** drugs to come to market. 9 ... Involve the administration of single sub-therapeutic doses to a small number of ... those patients utilizing standard diagnostic studies or



全部

图片

新闻

视频

购物

更多

设置

工具

找到约 250,000 条结果 (用时 0.61 秒)

包含以下查询字词的结果: **Positioning of old and new *biologics* and small molecules in the treatment of inflammatory bowel diseases**

仅搜索: Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases

Biologic targeting in the treatment of inflammatory bowel diseases

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726060/> - 翻译此页

作者: M Bosani - 2009 - 被引用次数: 141 - 相关文章

2009年7月13日 - Controlled clinical trials are currently being conducted, exploring the safety and efficacy of **old and new** biologic agents, and the search certainly will open **new** and exciting perspective on the development of therapies for **inflammatory bowel disease**. A review is made of the main areas of research exploring ...

Emerging biologics in inflammatory bowel disease | SpringerLink

<https://link.springer.com/article/10.1007/s00535-016-1283-0> - 翻译此页

作者: HC Chan - 2017 - 被引用次数: 13 - 相关文章

In addition, the use of **biologics** is currently limited by their cost, especially in developing countries. A number of **new** therapeutic targets, including novel **small molecules**, and cellular therapy are available or under investigation. These novel molecules include oral Janus kinase (JAK) inhibitor (tofacitinib), interleukin inhibitor ...



Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases



全部

图片

新闻

视频

购物

更多

设置

工具

找到约 4,800,000 条结果 (用时 0.55 秒)

您是不是要找: **Positioning of old and new *biologics* and small molecules in the treatment of inflammatory bowel diseases**

Established Management Paradigms in IBD: Treatment ... - Nature

<https://www.nature.com/articles/ajgsup201616.pdf?origin=ppub> - 翻译此页

作者: MD Regueiro - 2016 - 被引用次数: 2 - 相关文章

Inflammatory bowel disease affects approximately 1.6 million ... of 263 per 100,000 individuals in those **aged** over 20 years **old** and ... **management** of patients with ulcerative colitis (UC) and Crohn's disease, controversy tically significant, the differences were **small** and of uncertain AGA medical **position** statement on.

Established Management Paradigms in IBD: Treatment Targets and ...

<https://www.nature.com/.../clinical-and-systematic-review> - 翻译此页

作者: MD Regueiro - 2016 - 被引用次数: 2 - 相关文章

2016年12月1日 - **Inflammatory bowel disease** affects 1.6 million Americans. ... 100,000 individuals in those **aged** over 20 years **old** and of Crohn's disease in 241/100,000 individuals. the differences were **small** and of uncertain clinical relevance. AGA medical **position** statement on the diagnosis and **management** of ...

Emerging biologics in inflammatory bowel disease | SpringerLink

<https://link.springer.com/article/10.1007/s00535-016-1283-0> - 翻译此页

作者: HC Chan - 2017 - 被引用次数: 18 - 相关文章

Early biologic therapy is recommended in patients with **inflammatory bowel disease** and poor ... A number of **new** therapeutic targets, including novel **small molecules**, and cellular ... at lower cost with similar efficacy, and are also available for the **treatment** of IBD. **Position** of **new biologics** in the **treatment** paradigm of IBD.

ECCO position statement: The use of biosimilar medicines in the ...

<https://academic.oup.com/ecco-jcc/article-pdf/7/7/586/.../7-7-586.pdf> - 翻译此页

作者: S Danese - 2013 - 被引用次数: 135 - 相关文章

Biologics have become key agents for the **management** of Crohn's disease ... European specialist in